Senocohort: Identification of Predictive Biomarkers in Breast Cancer Treatment

NCT07833891 | Not Yet Recruiting

• 1 other identifier: APHP241257
• Study Type: observational
• Target: 500
• Locations: 0 countries
• Sites: N/A

Brief Summary

Breast cancer is a heterogeneous disease with multiple molecular subtypes, each requiring tailored therapeutic strategies. The recent introduction of targeted therapies, immunotherapies, and antibody-drug conjugates has expanded treatment options, yet their efficacy varies depending on tumor subtype. This non-interventional study aims to identify novel predictive biomarkers of response or resistance to these emerging therapies. The Senocohort study will prospectively collect clinical, biological, imaging, and organoid-derived data from breast cancer patients, with a focus on hormone receptor-negative tumors. The ultimate goal is to improve precision medicine strategies and patient stratification

Conditions

Breast Cancer; Breast Cancer (Triple Negative Type)

Keywords

hormone receptor-negative breast cancer; Breast neoplasms; Biomarkers; Precision medicine; Tumor organoids; Predictive biomarkers; Triple-Negative Breast Neoplasms; Circulating DNA; Patient-Derived Organoid; Immunotherapy

Outcome Measures

Primary Outcomes (1)

• Number of Predictive Multimodal Biomarkers identified

  Discovery and validation of molecular, cellular, and imaging biomarkers associated with response or resistance to therapies, evaluated on progression-free survival.

  Up to 10 years

Secondary Outcomes (3)

• Overall Survival Analysis by Biomarker Subgroup

  Up to 10 years

• Multimodal biomarker performance

  Up to 10 years

• Drug Sensitivity in PDO Models

  Up to 10 years

Study Arms (1)

Breast Cancer Patients at Saint-Louis Hospital

Patients with newly diagnosed or recurrent breast cancer managed at the breast surgery and senology units. Residual tumor tissue, blood, and clinical data will be collected for analysis.

Other: Patients follow-up

Interventions

Patients follow-up OTHER

Blood sampling, residual tissue material collection and clinical data collection

Breast Cancer Patients at Saint-Louis Hospital

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients aged 18 or older with a histologically confirmed diagnosis of breast cancer, treated at the Saint-Louis Hospital senology and breast surgery departments. Emphasis will be placed on hormone receptor-negative subtypes.

You may qualify if:

• Age ≥ 18 years
• Histologically confirmed breast cancer
• Managed at Saint-Louis Hospital
• No opposition to participation in research
• Affiliation to the French national health system

You may not qualify if:

• Expressed opposition to research
• Legal incapacity or under legal protection
• Patients under State Medical Aid (AME)

Sponsors & Collaborators

• Assistance Publique - Hôpitaux de Paris: lead

Biospecimen

Retention: SAMPLES WITHOUT DNA

Residual tissue material Additional blood sampling

MeSH Terms

Conditions

Breast Neoplasms; Triple Negative Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Central Study Contacts

Luis Texeira, MD PhD

CONTACT

01 42 49 96 13; luis.teixeira@aphp.fr

Jérôme Lambert, MD PhD

CONTACT

0142499742; jerome.lambert@u-paris.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 16, 2026
• First Posted: September 22, 2026
• Study Start: October 1, 2026
• Primary Completion (Estimated): October 1, 2031
• Study Completion (Estimated): October 1, 2041
• Last Updated: September 22, 2026

Record last verified: 2026-09